SCHEMBL6999731

SCHEMBL6999731

CC1Oc2ccc(CNCc3ccc(Cl)cc3)cc2NC1=O

nearest known ligand 0.80

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 11/20 0.80
POLB P06746 2/20 0.52
TP53 P04637 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
USP2 O75604 1/20 0.47
HSD17B10 Q99714 1/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302991 0.94 PARP1 (0.90) PARP1POLBTP53SMN1; SMN2USP2
SCHEMBL6996295 0.89 PARP1 (0.78) PARP1POLBTP53SMN1; SMN2HSD17B10
SCHEMBL7000032 0.89 PARP1 (0.74) PARP1POLBTP53SMN1; SMN2PDE3B
SCHEMBL532477 0.89 PARP1 (1.00) PARP1POLBTP53SMN1; SMN2HSD17B10
SCHEMBL7003151 0.89 PARP1 (0.81) PARP1POLBTP53SMN1; SMN2USP2
SCHEMBL7000465 0.89 PARP1 (0.67) PARP1POLBTP53SMN1; SMN2USP2
SCHEMBL6305046 0.88 PARP1 (0.77) PARP1POLBTP53SMN1; SMN2HSD17B10
SCHEMBL6303081 0.88 PARP1 (0.80) PARP1POLBTP53SMN1; SMN2USP2
SCHEMBL6995652 0.88 PARP1 (0.80) PARP1POLBTP53SMN1; SMN2PDE3B
SCHEMBL6305288 0.87 PARP1 (0.88) PARP1POLBTP53SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed